FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain Cancer
TUCSON, Ariz.--(BUSINESS WIRE)-- April 13, 2017 Nuvox Pharma announces that the FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial for its oxygen therapeutic, NVX-108, in patients with the hypoxic...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Investigational New Drugs | Neurology | Pharmaceuticals